Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The effect of haematopoietic growth factors on neutrophil recovery after allogeneic bone
marrow transplantation is well recognized. Recent laboratory studies demonstrated that these
cytokines may also modify T-cell and dendritic cell function, but whether the effect is
strong enough to alter the risk of graft-versus-host disease (GvHD) is unclear.
The aim of this randomised study is to determine the effect of granulocyte colony-stimulating
factor [G-CSF] (Neupogen; filgrastim) on the risk of acute GvHD after allogeneic bone marrow
transplantation.